Millennium Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $148M | Buy |
447,887
+372,457
| +494% | +$127M | 0.06% | 300 |
|
|
2025
Q4 | $30M | Sell |
75,430
-474,501
| -86% | -$210M | 0.01% | 1190 |
|
|
2025
Q3 | $251M | Buy |
549,931
+459,486
| +508% | +$187M | 0.11% | 145 |
|
|
2025
Q2 | $29.5M | Sell |
90,445
-196,892
| -69% | -$54.5M | 0.01% | 1216 |
|
|
2025
Q1 | $77.6M | Sell |
287,337
-46,105
| -14% | -$11.8M | 0.04% | 496 |
|
|
2024
Q4 | $78.5M | Buy |
333,442
+82,479
| +33% | +$21.7M | 0.04% | 514 |
|
|
2024
Q3 | $69M | Buy |
250,963
+112,459
| +81% | +$29.3M | 0.03% | 630 |
|
|
2024
Q2 | $33.7M | Sell |
138,504
-63,774
| -32% | -$10.1M | 0.02% | 1064 |
|
|
2024
Q1 | $30.2M | Buy |
202,278
+165,742
| +454% | +$27.6M | 0.01% | 1188 |
|
|
2023
Q4 | $6.99M | Buy |
36,536
+20,429
| +127% | +$3.48M | ﹤0.01% | 2500 |
|
|
2023
Q3 | $2.85M | Sell |
16,107
-58,873
| -79% | -$11.2M | ﹤0.01% | 3225 |
|
|
2023
Q2 | $14.2M | Buy |
74,980
+51,606
| +221% | +$10.2M | 0.01% | 1693 |
|
|
2023
Q1 | $4.68M | Buy |
+23,374
| New | +$4.91M | ﹤0.01% | 2661 |
|
|
2022
Q4 | – | Sell |
-172,770
| Closed | -$36.9M | – | 6541 |
|
|
2022
Q3 | $34.6M | Buy |
172,770
+168,318
| +3,781% | +$32.1M | 0.02% | 917 |
|
|
2022
Q2 | $649K | Sell |
4,452
-59,505
| -93% | -$8.44M | ﹤0.01% | 4747 |
|
|
2022
Q1 | $10.4M | Sell |
63,957
-19,460
| -23% | -$2.96M | 0.01% | 2120 |
|
|
2021
Q4 | $14.1M | Buy |
83,417
+71,585
| +605% | +$13.3M | 0.01% | 1778 |
|
|
2021
Q3 | $2.23M | Buy |
11,832
+1,711
| +17% | +$321K | ﹤0.01% | 3778 |
|
|
2021
Q2 | $1.72M | Sell |
10,121
-65,659
| -87% | -$9.62M | ﹤0.01% | 4145 |
|
|
2021
Q1 | $10.7M | Sell |
75,780
-44,563
| -37% | -$6.71M | 0.01% | 1697 |
|
|
2020
Q4 | $15.6M | Buy |
120,343
+115,143
| +2,214% | +$15.4M | 0.01% | 1278 |
|
|
2020
Q3 | $757 | Buy |
5,200
+839
| +19% | +$119K | ﹤0.01% | 3324 |
|
|
2020
Q2 | $646K | Sell |
4,361
-96,410
| -96% | -$13M | ﹤0.01% | 3247 |
|
|
2020
Q1 | $11M | Sell |
100,771
-17,491
| -15% | -$2.02M | 0.02% | 800 |
|
|
2019
Q4 | $13.6M | Sell |
118,262
-98,962
| -46% | -$9.87M | 0.02% | 1121 |
|
|
2019
Q3 | $17.5M | Buy |
217,224
+63,166
| +41% | +$5M | 0.03% | 873 |
|
|
2019
Q2 | $11.2M | Buy |
+154,058
| New | +$11.8M | 0.02% | 1159 |
|
|
2019
Q1 | – | Sell |
-11,373
| Closed | -$829K | – | 3946 |
|
|
2018
Q4 | $829K | Buy |
+11,373
| New | +$875K | ﹤0.01% | 2677 |
|
|
2018
Q3 | – | Sell |
-2,182
| Closed | -$215K | – | 3859 |
|
|
2018
Q2 | $215K | Buy |
+2,182
| New | +$216K | ﹤0.01% | 3535 |
|
|
2017
Q4 | – | Sell |
-51,125
| Closed | -$6.01M | – | 3762 |
|
|
2017
Q3 | $6.01M | Buy |
+51,125
| New | +$4.36M | 0.01% | 1560 |
|
|
2017
Q2 | – | Sell |
-11,631
| Closed | -$596K | – | 3419 |
|
|
2017
Q1 | $596K | Sell |
11,631
-217,609
| -95% | -$10.1M | ﹤0.01% | 2719 |
|
|
2016
Q4 | $8.58M | Buy |
229,240
+217,283
| +1,817% | +$9.1M | 0.02% | 1012 |
|
|
2016
Q3 | $810K | Sell |
11,957
-68,416
| -85% | -$4.83M | ﹤0.01% | 2380 |
|
|
2016
Q2 | $4.46M | Sell |
80,373
-162,830
| -67% | -$10.3M | 0.01% | 1332 |
|
|
2016
Q1 | $15.3M | Buy |
243,203
+206,690
| +566% | +$13.7M | 0.04% | 603 |
|
|
2015
Q4 | $3.44M | Buy |
+36,513
| New | +$3.39M | 0.01% | 1609 |
|
|
2015
Q3 | – | Sell |
-50,950
| Closed | -$6.11M | – | 3425 |
|
|
2015
Q2 | $6.11M | Sell |
50,950
-28,565
| -36% | -$3.41M | 0.01% | 1275 |
|
|
2015
Q1 | $8.3M | Buy |
+79,515
| New | +$8.06M | 0.02% | 1129 |
|
|
2014
Q3 | – | Sell |
-20,313
| Closed | -$1.28M | – | 3660 |
|
|
2014
Q2 | $1.28M | Sell |
20,313
-107,042
| -84% | -$6.36M | ﹤0.01% | 2048 |
|
|
2014
Q1 | $8.55M | Buy |
127,355
+121,944
| +2,254% | +$9.44M | 0.02% | 899 |
|
|
2013
Q4 | $348K | Sell |
5,411
-62,562
| -92% | -$3.73M | ﹤0.01% | 2948 |
|
|
2013
Q3 | $4.35M | Buy |
+67,973
| New | +$3.39M | 0.01% | 1202 |
|
Other funds holding ALNY
VPM
VCM
Millennium Management's ALNY Position: Q1 2026 in Review
Millennium Management increased its Alnylam Pharmaceuticals (ALNY) stake by 494% in Q1 2026, buying an estimated $127M and bringing the position to 447,887 shares worth $148M. The position accounts for 0.06% of the portfolio, ranked #300.
Millennium Management first reported a position in ALNY in Q3 2013 and has held it in 42 quarters since. The position peaked at $251M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Millennium Management held 447,887 shares of Alnylam Pharmaceuticals worth $148M as of Q1 2026.
- Millennium Management bought 372,457 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $127M.
- Alnylam Pharmaceuticals made up 0.06% of Millennium Management's portfolio in Q1 2026, its #300 holding.
- Millennium Management first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 42 quarters since.
- Millennium Management's Alnylam Pharmaceuticals position peaked at $251M in Q3 2025.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.